• If you are wondering whether Elevance Health at around US$376.63 offers good value or not, it helps to break the story into what the price has done lately and what the fundamentals suggest about fair value.
• The share price has moved sharply in the short term, with a 14.8% return over the last 7 days and 32.2% over the last 30 days, while the 1 year return of negative 8.5% and 3 year return of negative 13.7% tell a different story to the 5 year return of 3.9% and the year to date return of 6.3%.
• Recent coverage around Elevance Health has focused on its role in the broader US healthcare system and ongoing attention on large managed-care players. This can affect how investors think about long term demand and policy risk. This context helps explain why sentiment can shift quickly, even when the core business model appears steady to outside observers.
• On Simply Wall St's valuation checks, Elevance Health has a value score of 5 out of 6. The next step is to compare what different valuation methods suggest the shares might be worth and then look at an even deeper way of thinking about value at the end of this article.

Approach 1: Elevance Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a business could generate in future, then discounts those cash flows back to today to arrive at an estimate of what the whole company might be worth now.

For Elevance Health, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $6.30b. Analysts provide explicit free cash flow estimates only for the earlier years, with Simply Wall St extrapolating further out. In this model, projected free cash flow for 2030 is $8.77b. Intermediate years such as 2026 to 2029 range from about $5.81b to $5.96b on a discounted basis.

After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $1,084.10 per share. Compared with the current share price of around $376.63, this implies the stock is about 65.3% undervalued according to this method.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Elevance Health is undervalued by 65.3%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Approach 2: Elevance Health Price vs Earnings

For profitable companies like Elevance Health, the P/E ratio is a straightforward way to relate what you pay for each share to the earnings that support it. It helps you see how much the market is willing to pay for each dollar of profit.

What counts as a “normal” P/E depends on how quickly earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can justify a higher P/E, while lower growth or higher risk usually points to a lower multiple.

Elevance Health currently trades on a P/E of 15.60x. That is below the Healthcare industry average P/E of 24.57x and the peer group average of 34.73x, so on simple comparisons the stock trades on a lower multiple than many peers.

Simply Wall St’s Fair Ratio for Elevance Health is 30.89x. This is a proprietary estimate of what a “normal” P/E might be for the company, based on factors such as earnings growth, profit margins, industry, market cap and key risks. Because it ties the multiple to Elevance Health’s own characteristics rather than broad group averages, it can give a more tailored view than simple peer or industry comparisons.

Comparing the Fair Ratio of 30.89x with the current P/E of 15.60x suggests the shares trade below this modelled level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Elevance Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are a simple way for you to attach a clear story about Elevance Health to your own numbers, linking what you believe about future revenue, earnings and margins to a forecast and then to a Fair Value that can be compared with today’s price.

On Simply Wall St’s Community page, Narratives are available as an easy tool used by millions of investors. You can set assumptions like revenue growth, profit margins and future P/E, and the platform then converts that story into an estimated Fair Value that updates automatically when fresh news or earnings are added.

For Elevance Health, one investor might lean toward a cautious Narrative that looks similar to the US$331.0 Fair Value case, with flatter revenue, modest margin improvement to about 3.15% and a future P/E near 12.07x. Another investor might prefer a more upbeat Narrative closer to the US$441.98 Fair Value case, which uses higher revenue, margins around 3.49% and a future P/E near 14.81x. By setting both side by side, you can quickly see how your own view compares with the current share price and decide what that difference means for your next move.

For Elevance Health however we will make it really easy for you with previews of two leading Elevance Health Narratives:

Fair value in this bullish narrative: US$390.54 per share.

Gap to that fair value versus the current US$376.63 share price: about 3.6% below the narrative fair value.

Revenue growth used in this narrative: 679.28%.

• Sees Elevance Health as a large, diversified health benefits group with exposure across commercial, Medicare and Medicaid that can support resilience.
• Highlights growth themes tied to Medicare Advantage, value based care and digital health, alongside a history of dividend growth and a low payout ratio.
• Flags pressures around Medicaid membership, benefit costs, regulation and competition, but treats them as risks that can be managed over time.

Fair value in this bearish narrative: US$331.00 per share.

Gap to that fair value versus the current US$376.63 share price: about 13.8% above the narrative fair value.

Revenue growth used in this narrative: 69.96%.

• Focuses on higher medical costs in ACA and Medicaid plans, slow rate alignment and greater use of value based care as potential margin headwinds.
• Emphasizes regulatory and policy uncertainty, provider bargaining power and acquisition integration as sources of earnings volatility.
• Builds a fair value of US$331.00 using flatter revenue assumptions, modest margin improvement and a lower future P/E multiple than the current one.

Taken together, these narratives show how different views on costs, regulation and growth can lead to quite different estimates of what Elevance Health might be worth. You can use these as a guide when setting your own assumptions and next steps.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Elevance Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.